Preliminary results from a phase 1/2 study of INCB054828, a highly selective fibroblast growth factor receptor (FGFR) inhibitor, in patients with advanced malignancies

被引：8
|
作者：
Saleh, Mansoor
Gutierrez, Martin E.
Subbiah, Vivek
Smith, David C.
Asatiani, Ekaterine
Lihou, Christine F.
Zhen, Huiling
Yeleswaram, Swamy
Ji, Tao
Nemunaitis, John
机构：
来源：
CANCER RESEARCH | 2017年 / 77卷
关键词：
D O I：
10.1158/1538-7445.AM2017-CT111
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
CT111
引用
收藏
页数：2
相关论文
共 50 条
  • [11] Activity of the selective FGFR 1, 2 and 3 inhibitor INCB054828 in genetically-defined models of triple-negative breast cancer
    Liu, Phillip C. C.
    Lehmann, Brian D.
    Ruggeri, Bruce
    DiMatteo, Darlise
    Schafer, Johanna M.
    Lu, Jin
    Lee, Sang Hyun
    Lin, Luping
    Burn, Timothy C.
    Diamond, Melody
    Volgina, Alla
    Wu, Liangxing
    Hollis, Gregory
    Huber, Reid
    Pietenpol, Jennifer A.
    Scherle, Peggy
    CANCER RESEARCH, 2017, 77
  • [12] A phase III study of INCB054828 as adjuvant therapy in patients (pts) with high-risk urothelial carcinoma (UC) harboring fibroblast growth factor receptor 3 (FGFR3) genomic alterations
    Necchi, A.
    Perez-Gracia, J. L.
    Loriot, Y.
    Witjes, W.
    Montorsi, F.
    Bjartell, A.
    Shariat, S. F.
    ANNALS OF ONCOLOGY, 2018, 29
  • [13] Interim results of fight-202, a phase II, open-label, multicenter study of INCB054828 in patients (pts) with previously treated advanced/metastatic or surgically unresectable cholangiocarcinoma (CCA) with/without fibroblast growth factor (FGF)/FGF receptor (FGFR) genetic alterations
    Hollebecque, A.
    Borad, M.
    Sahai, V.
    Catenacci, D. V. T.
    Murphy, A.
    Vaccaro, G.
    Paulson, A.
    Oh, D-Y.
    Feliz, L.
    Lihou, C.
    Zhen, H.
    Abou-Alfa, G. K.
    ANNALS OF ONCOLOGY, 2018, 29 : 258 - 258
  • [14] Preliminary Results from an Ongoing Phase 1/2 Study of INCB057643, a Bromodomain and Extraterminal (BET) Protein Inhibitor, in Patients (pts) with Advanced Malignancies
    Forero-Torres, Andres
    Rosen, Seth
    Smith, David C.
    Lesser, Glenn
    Peguero, Julio
    Gupta, Shilpa
    Watts, Justin M.
    Noel, Marcus
    Kurzrock, Razelle
    Park, Haeseong
    LoRusso, Patricia
    Coombs, Catherine C.
    Zheng, Fred
    Switzky, Julie
    Yeleswaram, Swamy
    Falchook, Gerald
    BLOOD, 2017, 130
  • [15] Results of a phase I study of AZD4547, an inhibitor of fibroblast growth factor receptor (FGFR), in patients with advanced solid tumors.
    Andre, Fabrice
    Ranson, Malcolm
    Dean, Emma
    Varga, Andrea
    van der Noll, Ruud
    Stockman, Paul K.
    Ghiorghiu, Dana
    Kilgour, Elaine
    Smith, Paul D.
    Macpherson, Merran
    Lawrence, Peter
    Hastie, Andrew
    Schellens, Jan H. M.
    CANCER RESEARCH, 2013, 73 (08)
  • [16] Interim results of fight-201, a phase II, open-label, multicenter study of INCB054828 in patients (pts) with metastatic or surgically unresectable urothelial carcinoma (UC) harboring fibroblast growth factor (FGF)/FGF receptor (FGFR) genetic alterations (GA)
    Necchi, A.
    Pouessel, D.
    Leibowitz-Amit, R.
    Flechon, A.
    Gupta, S.
    Barthelemy, P.
    Maio, M.
    Zhu, X.
    Asatiani, E.
    Serbest, G.
    Zhen, H.
    Loriot, Y.
    ANNALS OF ONCOLOGY, 2018, 29
  • [17] Preliminary results of a phase 1 study of FP-1039 (FGFR1:Fc), a novel antagonist of multiple fibroblast growth factor (FGF) ligands, in patients with advanced malignancies
    Tolcher, Anthony
    Papadopoulos, Kyri
    Agnew, Jim
    Marshall, John
    Tanzola, Carolyn
    Zanghi, Jim
    Baker, Kevin P.
    Keer, Harold N.
    Patniak, Amita
    MOLECULAR CANCER THERAPEUTICS, 2009, 8 (12)
  • [18] Discovery of LHQ490 as a highly selective fibroblast growth factor receptor 2 (FGFR2) inhibitor
    Li, Huiqiong
    Ke, Ran
    Zhou, Yang
    Chang, Shaohua
    Wang, Jie
    Su, Chen
    Wu, Pinglian
    Yang, Bowen
    Wang, Zhen
    Ding, Ke
    Ma, Dawei
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2024, 272
  • [19] Safety and activity of the pan-fibroblast growth factor receptor (FGFR) inhibitor erdafitinib in phase 1 study patients with advanced urothelial carcinoma
    Soria, J-C.
    Italiano, A.
    Cervantes, A.
    Tabernero, J.
    Infante, J.
    Lara, P. N.
    Spira, A.
    Calvo, E.
    Moreno, V.
    Blay, J-Y.
    Lauer, R.
    Chan, N.
    Zhong, B.
    Santiago-Walker, A. Ademi
    Bussolari, J.
    Luo, F. R.
    Xie, H.
    Hammerman, P.
    ANNALS OF ONCOLOGY, 2016, 27
  • [20] Phase 1 study of JNJ-42756493, a pan-fibroblast growth factor receptor (FGFR) inhibitor, in patients with advanced solid tumors
    Bahleda, Rastislav
    Dienstmann, Rodrigo
    Adamo, Barbara
    Gazzah, Anas
    Infante, Jeffrey R.
    Zhong, Bob
    Platero, Suso J.
    Smit, Hans
    Perera, Timothy
    Stuyckens, Kim
    Bussolari, Jacqueline
    Poddareddigari, Vijay
    Soria, Jean-Charles
    Luo, Feng Roger
    Tabernero, Josep
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
12345